Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Clinical Laserthermia Systems AB
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\>18 years of age
histologically confirmed malignant melanoma
advanced melanoma disease (Stage III inoperable or Stage IV) that has progressed on standard first line treatment such as kinase inhibitor(s) and/or immunoregulatory monoclonal antibodies. Previously untreated patients with a dominant tumour lesion deemed suitable for local and highly tumour-destructive ablation may also be included
time interval between previous systemic treatment and imILT of at least one month
at least one lesion located in such a way (typically subcutaneously) that it can be treated without risk of skin necrosis or serious damage to other adjacent vital and healthy tissue
verbal and written informed consent to participate
adequate haematologic, renal and hepatic functions
have an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
You may not be if
known HIV infection
autoimmune disease which is judged to reduce an anti-tumour immune response
systemic corticosteroid medication
bleeding diathesis
pregnancy or breast-feeding
Clareo Health | Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
